We are live on ! Find out more
SCM

Stonepine Capital Management Portfolio holdings

AUM $250M
1-Year Est. Return 77.6%
This Fund
S&P 500
This Quarter Est. Return
+9.46%
1 Year Est. Return
+77.6%
3 Year Est. Return
+198.76%
5 Year Est. Return
+226.15%
10 Year Est. Return
+1,976.54%
AUM
$84.8M
AUM Growth
-$567K
Cap. Flow
+$3.88M
Cap. Flow %
4.58%
Top 10 Hldgs %
92.87%
Holding
21
New
7
Increased
6
Reduced
4
Closed
2

Top Buys

1
SCLN
Sciclone Pharmaceuticals Inc
SCLN
+$7.76M
2
CUTR
Cutera, Inc.
CUTR
+$3.09M
3
ZLTQ
ZELTIQ Aesthetics, Inc.
ZLTQ
+$1.65M
4
PTX
Pernix Therapeutics Holdings, Inc.
PTX
+$1.45M
5
VNDA icon
Vanda Pharmaceuticals
VNDA
+$1.23M

Top Sells

1
CTIC
CTI BioPharma Corp. (DE) Common Stock
CTIC
+$5.56M
2
FMI
Foundation Medicine, Inc.
FMI
+$3.64M
3
ENTA icon
Enanta Pharmaceuticals
ENTA
+$2.35M
4
SGNT
SAGENT PHARMACEUTICALS INC COM STK (DE)
SGNT
+$1.82M
5
FLNA
Filana Therapeutics
FLNA
+$82.4K

Sector Composition

1 Healthcare 92.31%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SCLN
1
DELISTED
Sciclone Pharmaceuticals Inc
SCLN
$22.5M 26.58%
2,048,638
+873,064
+74% +$7.76M
VNDA icon
2
Vanda Pharmaceuticals
VNDA
$327M
$17.3M 20.39%
2,068,297
+149,368
+8% +$1.23M
VCEL icon
3
Vericel Corp
VCEL
$2.38B
$8.31M 9.8%
1,417,939
+41,052
+3% +$115K
FLNA
4
Filana Therapeutics
FLNA
$51.2M
$7.87M 9.28%
504,343
-6,371
-1% -$82.4K
TBRA
5
DELISTED
Tobira Therapeutics, Inc. Common Stock
TBRA
$6.81M 8.04%
832,977
-400
-0% -$3.02K
CUTR
6
DELISTED
Cutera, Inc.
CUTR
$4.19M 4.94%
372,300
+272,300
+272% +$3.09M
SGNT
7
DELISTED
SAGENT PHARMACEUTICALS INC COM STK (DE)
SGNT
$4.05M 4.78%
333,065
-129,759
-28% -$1.82M
PTX
8
DELISTED
Pernix Therapeutics Holdings, Inc.
PTX
$3.38M 3.98%
321,586
+73,121
+29% +$1.45M
CTIC
9
DELISTED
CTI BioPharma Corp. (DE) Common Stock
CTIC
$1.99M 2.35%
374,334
-695,528
-65% -$5.56M
ZLTQ
10
DELISTED
ZELTIQ Aesthetics, Inc.
ZLTQ
$1.9M 2.24%
+70,000
New +$1.65M
DSCI
11
DELISTED
Derma Sciences, Inc. Common Stock (DE)
DSCI
$1.57M 1.86%
507,799
– –
SCTL
12
DELISTED
Societal CDMO, Inc. Common Stock
SCTL
$1.41M 1.67%
264,115
+133,770
+103% +$825K
BSTC
13
DELISTED
BioSpecifics Technologies Corp.
BSTC
$893K 1.05%
+25,637
New +$941K
RPTP
14
DELISTED
RAPTOR PHARMACEUTICAL CORP COM STK (DE)
RPTP
$92K 0.11%
+20,000
New +$80.4K
SCMP
15
DELISTED
Sucampo Pharmaceuticals, Inc.
SCMP
$57K 0.07%
+5,228
New +$66.1K
ANIP icon
16
ANI Pharmaceuticals
ANIP
$1.8B
$56K 0.07%
+1,650
New +$56K
INSY
17
DELISTED
Insys Therapeutics, Inc.
INSY
$32K 0.04%
+2,000
New +$38K
BDSI
18
DELISTED
BioDelivery Sciences International, Inc.
BDSI
$28K 0.03%
+8,523
New +$31.5K
ENTA icon
19
Enanta Pharmaceuticals
ENTA
$400M
– –
-71,147
Closed -$2.35M
FMI
20
DELISTED
Foundation Medicine, Inc.
FMI
– –
-173,049
Closed -$3.64M

Similar funds

BIA
Bigelow Investment Advisors Portland, Maine $250M AUM 19.33% 1-Year Est. Return
TGP
TMT General Partner Hong Kong $250M AUM 6.05% 1-Year Est. Return
ER
EVR Research Richmond, Virginia $250M AUM 41.5% 1-Year Est. Return
FDDB
Fidelity D&D Bancorp Dunmore, Pennsylvania $249M AUM 18.9% 1-Year Est. Return
VM
VPR Management Houston, Texas $250M AUM 34.13% 1-Year Est. Return
PF
Parker Financial Silverdale, Washington $250M AUM 14.69% 1-Year Est. Return
SCM
Step Capital Management Singapore $249M AUM
CWM
Chicago Wealth Management Chicago, Illinois $251M AUM 45.31% 1-Year Est. Return

Stonepine Capital Management's Q1 2016 Portfolio in Review

As of Q1 2016, Stonepine Capital Management held 21 positions worth $84.8M, down 0.66% from $85.4M the previous quarter. Its ten largest holdings account for 93% of the portfolio.

Stonepine Capital Management deployed $3.88M of net new capital in Q1 2016, opening 7 new positions and adding to 6 existing holdings. Its largest new stake was ZELTIQ Aesthetics, Inc.: 70,000 shares worth $1.9M.

By sector, the portfolio is most concentrated in Healthcare at 92% of assets, up from 91% a quarter earlier.

On the sell side, the largest reduction was CTI BioPharma Corp. (DE) Common Stock, an estimated $5.56M trimmed.

  • Stonepine Capital Management's largest Q1 2016 buy was ZELTIQ Aesthetics, Inc.: 70,000 shares worth $1.9M.
  • Stonepine Capital Management added most to Sciclone Pharmaceuticals Inc in Q1 2016, an estimated $7.76M increase.
  • Stonepine Capital Management's biggest Q1 2016 reduction was CTI BioPharma Corp. (DE) Common Stock, cutting an estimated $5.56M.
  • Stonepine Capital Management fully exited Foundation Medicine, Inc. in Q1 2016, selling an estimated $3.64M.
  • Stonepine Capital Management's ten largest holdings make up 93% of its $84.8M portfolio in Q1 2016.
  • Stonepine Capital Management opened 7 new positions and closed 2 in Q1 2016.
  • Stonepine Capital Management's portfolio value fell 0.66% quarter-over-quarter to $84.8M.

Based on Stonepine Capital Management's 13F filing for Q1 2016, filed 11 May 2016.